GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

11

Can Brain Stimulation Reduce Visceral Pain in IBS-D? Low-Frequency rTMS Shows Promise: Gut | September 2026

Introduction: Chronic visceral pain is one of the most difficult symptoms to treat in diarrhea-predominant IBS (IBS-D). This translational study identified medial prefrontal cortex (mPFC) hyperexcitability as a...

12

ACG Updates the Diagnosis and Management of Adenomatous Colorectal Polyposis Syndromes: AJG | September 2026

Introduction: Hereditary adenomatous polyposis syndromes are systemic cancer-predisposition disorders involving not only the colorectum but also the stomach, duodenum and other organs. The updated ACG guideline emphasises earlier...

13

IBD in Remission but Symptoms Persist (Rome Foundation–IOIBD Consensus): Gastroenterology | September 2026

Introduction: Up to one-third of patients with IBD report abdominal pain, altered bowel habits or bloating despite treatment, and approximately one-quarter remain symptomatic even in endoscopic or histologic...

14

How Do We Get More People Screened for Colorectal Cancer: Gastroenterology| September 2026

Introduction: CRC screening reduces incidence and mortality, yet participation remains suboptimal. This network meta-analysis of 76 randomized trials compared strategies for improving screening uptake. Why was this study...

15

High-Dose Vitamin D3 Fails to Improve Outcomes in Metastatic Colorectal Cancer (Phase III SOLARIS Trial): JAMA | September 2026

Introduction: Vitamin D has long attracted interest as a potential adjunctive treatment in colorectal cancer. Preclinical studies demonstrate antiproliferative, pro-differentiation, anti-inflammatory and immunomodulatory effects, while observational studies have...

16

Probiotics After Rifaximin May Reduce Relapse in IBS-D: JGH | August 2026

Introduction: Rifaximin can improve symptoms in diarrhoea-predominant irritable bowel syndrome (IBS-D), but relapse after treatment remains common. Because rifaximin alters the intestinal microbial environment, post-treatment microbiome modulation may...

17

Vancomycin Taper vs Fidaxomicin for Recurrent C. difficile Infection (OpTION Trial): NEJM Evidence | August 2026

Introduction: Recurrent Clostridioides difficile infection (CDI) remains a major clinical challenge, with recurrence occurring in up to one-third of patients after initial treatment. Although both vancomycin taper-and-pulse (VAN-TP)...

18

DPP-4 Inhibition targeting the Gut–Brain Axis in Parkinson's Disease: Gut | July 2026

Introduction: Increasing evidence suggests that Parkinson's disease (PD) may originate in the gut, with pathological α-synuclein spreading to the brain through the vagus nerve. This preclinical study investigated...

19

Adjuvant Aspirin in Colorectal Cancer: The Lancet Gastroenterology & Hepatology | July 2026

Introduction: Although aspirin has long been investigated as adjuvant therapy for colorectal cancer (CRC), the overall ASCOLT trial showed no improvement in disease-free survival (DFS). This translational analysis...

20

Anal High-Grade Squamous Intraepithelial Lesions (HSIL): BJS | March 2026

Introduction: Anal squamous cell carcinoma is an increasingly common but largely preventable cancer. Most cases arise from persistent high-risk human papillomavirus (HPV) infection, progressing through high-grade squamous intraepithelial...

Previous
12313
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer